Firms Awarded $69.5 Million for Allergan Pay-to-Delay Suit Work

June 15, 2020, 10:17 PM

The six law firms responsible for securing a $750 million settlement on behalf of pharmaceutical direct purchasers in a class action against Allergan subsidiary Forest Pharmaceuticals have been awarded $69.5 million in fees, according to a ruling today by the U.S. District Court for the Southern District of New York.

The settlement, approved in May, resolved allegations that Forest Laboratories accepted payments from Mylan Pharmaceuticals in exchange for delaying its launch of a generic version of the Alzheimer’s drug, Namenda. The award represents 9.3% of the common fund.

Chief Judge Colleen J. McMahon said she couldn’t approve the firms’ proposed ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.